Pathway link MTORC1-MAPK

mTORC1 ⊣ ERK / RSK (MAPK)

mTORC1 inhibits ERK / RSK (MAPK).

Blocking mTORC1 can backfire by releasing a brake on a different growth pathway (MAPK) – one reason mTOR-blocking drugs alone often aren't enough.

A second feedback arm: inhibiting mTORC1 releases a PI3K-dependent brake and MAPK signalling goes up. Together with S6K1-IRS1 this is why single-agent mTOR inhibition tends to be met by compensatory growth signalling.

The conditions it holds under

Single-study edge in this corpus. CAR2008 includes tumour biopsies from patients with advanced solid tumours treated with RAD001 (everolimus), in which MAPK activation depended on the dosing schedule, plus a mouse prostate cancer model, xenografts and cell lines.

Time it takes

hours

Step

indirect (through steps not drawn here)

Measured in

patient tumour biopsies (RAD001), mouse, human cells

Where in the cell

cytosol

Reaches people?

shown in people

How settled

settled in the literature

Studies behind it

Points the other way

No study in the Atlas contradicts this link. That means none in this curated set, not none in the literature.

Who has checked this

Checked by

No researcher outside the project has checked this link yet.

Curator sign-off

Not signed off yet. This link was drafted with AI help and has not been reviewed link by link; treat it as a proposal until it is.

Curated by

Oliver Barton, with AI help for drafting; see how links are checked.

“Inhibits” describes the effect on the target's activity, not on how much of it there is.

“How settled” describes how far researchers in the field agree. It is not the same as the sign-off above, which only says whether a named curator has checked this page.

If this link rests on your own work: a click on “This looks right” below, or a short note through “Report an error”, helps us more than anything else on this page.

← The whole pathway · This link as JSON